Girl Power in Glaucoma: The Role of Estrogen in Primary Open Angle Glaucoma
Research output: Contribution to journal › Review › Research › peer-review
Standard
Girl Power in Glaucoma : The Role of Estrogen in Primary Open Angle Glaucoma. / Fotesko, Kyrylo; Thomsen, Bo Schneider Vohra; Kolko, Miriam; Vohra, Rupali.
In: Cellular and Molecular Neurobiology, Vol. 42, 2022, p. 41–57.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Girl Power in Glaucoma
T2 - The Role of Estrogen in Primary Open Angle Glaucoma
AU - Fotesko, Kyrylo
AU - Thomsen, Bo Schneider Vohra
AU - Kolko, Miriam
AU - Vohra, Rupali
PY - 2022
Y1 - 2022
N2 - Estrogen is essential in maintaining various physiological features in women, and a decline in estrogen levels are known to give rise to numerous unfortunate symptoms associated with menopause. To alleviate these symptoms hormone replacement therapy with estrogen is often used, and has been shown to be fruitful in improving quality of life in women suffering from postmenopausal discomforts. An often forgotten condition associated with menopause is the optic nerve disorder, glaucoma. Thus, estrogen may also have an impact in maintaining the retinal ganglion cells (RGCs), which make up the optic nerve, thereby preventing glaucomatous neurodegeneration. This review aims to provide an overview of possible associations of estrogen and the glaucoma subtype, primary open-angle glaucoma (POAG), by evaluating the current literature through a PubMed-based literature search. Multiple in vitro and in vivo studies of RGC protection, as well as clinical and epidemiological data concerning the well-defined retinal neurodegenerative disorder POAG have been reviewed. Over all, deficiencies in retinal estrogen may potentially instigate RGC loss, visual disability, and eventual blindness. Estrogen replacement therapy may therefore be a beneficial future treatment. However, more studies are needed to confirm the relevance of estrogen in glaucoma prevention.
AB - Estrogen is essential in maintaining various physiological features in women, and a decline in estrogen levels are known to give rise to numerous unfortunate symptoms associated with menopause. To alleviate these symptoms hormone replacement therapy with estrogen is often used, and has been shown to be fruitful in improving quality of life in women suffering from postmenopausal discomforts. An often forgotten condition associated with menopause is the optic nerve disorder, glaucoma. Thus, estrogen may also have an impact in maintaining the retinal ganglion cells (RGCs), which make up the optic nerve, thereby preventing glaucomatous neurodegeneration. This review aims to provide an overview of possible associations of estrogen and the glaucoma subtype, primary open-angle glaucoma (POAG), by evaluating the current literature through a PubMed-based literature search. Multiple in vitro and in vivo studies of RGC protection, as well as clinical and epidemiological data concerning the well-defined retinal neurodegenerative disorder POAG have been reviewed. Over all, deficiencies in retinal estrogen may potentially instigate RGC loss, visual disability, and eventual blindness. Estrogen replacement therapy may therefore be a beneficial future treatment. However, more studies are needed to confirm the relevance of estrogen in glaucoma prevention.
KW - Estrogen
KW - Glaucoma
KW - Menopause
KW - Neuroprotection
U2 - 10.1007/s10571-020-00965-5
DO - 10.1007/s10571-020-00965-5
M3 - Review
C2 - 33040237
AN - SCOPUS:85092408158
VL - 42
SP - 41
EP - 57
JO - Cellular and Molecular Neurobiology
JF - Cellular and Molecular Neurobiology
SN - 0272-4340
ER -
ID: 250827949